(VIANEWS) – EQUASENS (EQS.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| EQUASENS (EQS.PA) | €71.00 | 1.34% | 28.59% |
| MEDISTIM (MEDI.OL) | kr282.00 | 1.33% | 33.83% |
| IBA (IBAB.BR) | €16.12 | 1.16% | 5.01% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. EQUASENS (EQS.PA)
1.34% Forward Dividend Yield and 28.59% Return On Equity
Equasens Société anonyme provides various IT solutions for the healthcare sector in Europe. It offers LGPI global services and OffiCentral solutions for managing pharmacies and their networks; OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, OffiCash, Offizzy, and OffiLocker solutions for pharmacists' business processes; and solutions for energizing the customer relationship with pharmacists comprising OffiTag, OffiTouch, OffiMédia, OffiConnect, automation systems, and customer loyalty programs. The company also provides My Pilot, an analytics and management tool; OffiLearning, an e-learning tool; and solutions for patient support and advice, such as compliance monitoring software, Multimeds, Automeds, and OffiTéléconsult, as well as pharmaceutical record and shared medical record services. In addition, it offers a ULTIMATE, a system combining optimized pharmacy management and improved patient support; FARMACLICK, a protocol for communications between pharmacies and wholesalers-distributors; DIFARM, a solution for wholesalers-distributors; PHARE, a retail management tool; SOPHIA, a pharmacy management application; OffiMédia POS display; eNephro to enhance the care of chronic renal failure patients; and TPE Pilot, a web-based application that simplifies the management and sharing of patient education programs. Further, the company provides NOVIACARE; CARELIB Domicile; CARELIB EHPAD; KAPELSE solutions; TITAN solutions; ANTHADINE software and MOBISOINS mobile tool; MICROSOINS, an in-home nursing care solution; and LOGICLIC. Additionally, it offers AXIGATE solutions to manage the entire patient care pathway; CHORUS platform; medical telesecretarial services for healthcare professionals; and equipment lease financing solutions. The company was incorporated in 1996 and is based in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.59%.
More news about EQUASENS.
2. MEDISTIM (MEDI.OL)
1.33% Forward Dividend Yield and 33.83% Return On Equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr3.84.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 73.42. Meaning, the purchaser of the share is investing kr73.42 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 33.83%.
Volume
Today’s last reported volume for MEDISTIM is 664 which is 93.66% below its average volume of 10479.
Revenue Growth
Year-on-year quarterly revenue growth grew by 30.6%, now sitting on 491.94M for the twelve trailing months.
Yearly Top and Bottom Value
MEDISTIM’s stock is valued at kr282.00 at 17:30 EST, way under its 52-week high of kr330.00 and way higher than its 52-week low of kr184.80.
More news about MEDISTIM.
3. IBA (IBAB.BR)
1.16% Forward Dividend Yield and 5.01% Return On Equity
Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for advance research in ConformalFLASH. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.
Earnings Per Share
As for profitability, IBA has a trailing twelve months EPS of €0.13.
PE Ratio
IBA has a trailing twelve months price to earnings ratio of 11.38. Meaning, the purchaser of the share is investing €11.38 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.01%.
Volume
Today’s last reported volume for IBA is 1039 which is 93.63% below its average volume of 16334.
Yearly Top and Bottom Value
IBA’s stock is valued at €16.12 at 17:30 EST, way below its 52-week high of €19.10 and way above its 52-week low of €11.76.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, IBA’s stock is considered to be oversold (<=20).
More news about IBA.
